ATE322496T1 - 4-phenylpyridin-derivate als neurokinin-1- rezeptor-antagonisten - Google Patents
4-phenylpyridin-derivate als neurokinin-1- rezeptor-antagonistenInfo
- Publication number
- ATE322496T1 ATE322496T1 AT01960529T AT01960529T ATE322496T1 AT E322496 T1 ATE322496 T1 AT E322496T1 AT 01960529 T AT01960529 T AT 01960529T AT 01960529 T AT01960529 T AT 01960529T AT E322496 T1 ATE322496 T1 AT E322496T1
- Authority
- AT
- Austria
- Prior art keywords
- neurokinin
- receptor antagonists
- phenylpyridine derivatives
- phenylpyridine
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00115846 | 2000-07-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE322496T1 true ATE322496T1 (de) | 2006-04-15 |
Family
ID=8169331
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT01960529T ATE322496T1 (de) | 2000-07-24 | 2001-07-20 | 4-phenylpyridin-derivate als neurokinin-1- rezeptor-antagonisten |
Country Status (38)
Country | Link |
---|---|
US (2) | US6576762B2 (de) |
EP (1) | EP1305319B1 (de) |
JP (1) | JP4118673B2 (de) |
KR (1) | KR100527214B1 (de) |
CN (1) | CN1192032C (de) |
AR (1) | AR029875A1 (de) |
AT (1) | ATE322496T1 (de) |
AU (2) | AU8200501A (de) |
BR (1) | BR0112695A (de) |
CA (1) | CA2416874C (de) |
CY (1) | CY1106113T1 (de) |
CZ (1) | CZ2003528A3 (de) |
DE (1) | DE60118569T2 (de) |
DK (1) | DK1305319T3 (de) |
EC (1) | ECSP034446A (de) |
ES (1) | ES2260265T3 (de) |
GT (1) | GT200100148A (de) |
HK (1) | HK1058360A1 (de) |
HR (1) | HRP20030031A2 (de) |
HU (1) | HU229231B1 (de) |
IL (2) | IL153837A0 (de) |
JO (1) | JO2321B1 (de) |
MA (1) | MA26933A1 (de) |
MX (1) | MXPA03000367A (de) |
MY (1) | MY129224A (de) |
NO (1) | NO20030353L (de) |
NZ (1) | NZ523452A (de) |
PA (1) | PA8522801A1 (de) |
PE (1) | PE20020258A1 (de) |
PL (1) | PL366173A1 (de) |
PT (1) | PT1305319E (de) |
RU (1) | RU2276139C2 (de) |
SI (1) | SI1305319T1 (de) |
TW (1) | TWI287003B (de) |
UY (1) | UY26851A1 (de) |
WO (1) | WO2002008232A1 (de) |
YU (1) | YU2803A (de) |
ZA (1) | ZA200300219B (de) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1103545B1 (de) * | 1999-11-29 | 2003-11-05 | F. Hoffmann-La Roche Ag | 2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramid |
AR039329A1 (es) | 2002-04-26 | 2005-02-16 | Lilly Co Eli | Derivados de triazol, antagonistas de receptor de taquicinina |
PT1501808E (pt) | 2002-04-26 | 2008-09-26 | Lilly Co Eli | Antagonistas de receptores taquiquininas |
AU2003300018A1 (en) * | 2002-10-11 | 2004-05-04 | Bristol-Myers Squibb Company | Process for the preparation of tri-nitrogen containing heteroaryl-diamine derivatives useful as pharmaceutical agents and methods of producing pharmaceutical agents |
US20060160794A1 (en) * | 2003-06-12 | 2006-07-20 | Amegadzie Albert K | Tachykinin receptor antagonists |
EP1643998B1 (de) * | 2003-07-03 | 2007-08-29 | F. Hoffmann-La Roche Ag | Duale nk1/nk3 antagonisten zur behandlung von schizophrenie |
TWI280239B (en) | 2003-07-15 | 2007-05-01 | Hoffmann La Roche | Process for preparation of pyridine derivatives |
MX2007000198A (es) | 2004-07-06 | 2007-03-15 | Hoffmann La Roche | Proceso para la preparacion de derivados de carboxamida-piridina utilizados como intermediarios en la sintesis de antagonistas del receptor nk-1. |
US20060030600A1 (en) * | 2004-08-06 | 2006-02-09 | Patrick Schnider | Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia |
AU2005286733B2 (en) * | 2004-09-23 | 2009-11-05 | Alexander Michalow | Methods for regulating neurotransmitter systems by inducing counteradaptations |
US20080045610A1 (en) * | 2004-09-23 | 2008-02-21 | Alexander Michalow | Methods for regulating neurotransmitter systems by inducing counteradaptations |
CA2598762A1 (en) | 2005-02-25 | 2006-08-31 | F. Hoffmann-La Roche Ag | Tablets with improved drug substance dispersibility |
US8067662B2 (en) | 2009-04-01 | 2011-11-29 | Aalnex, Inc. | Systems and methods for wound protection and exudate management |
US7816577B2 (en) | 2006-02-13 | 2010-10-19 | Aalnex, Inc. | Wound shield |
ES2328185T3 (es) | 2006-05-31 | 2009-11-10 | F. Hoffmann-La Roche Ag | Derivados de aril-4-etinil-isoxazol. |
EP2129381A1 (de) | 2007-01-24 | 2009-12-09 | Glaxo Group Limited | Pharmazeutische zubereitungen enthaltend 3,5-diamino-6-(2,3-dichlophenyl)-1,2,4-triazin or r(-)-2,4-diamino-5-(2,3dichlorophenyl)-6-fluoromethyl pyrimidin und einen nk1- rezeptor-antagonisten |
GB0808747D0 (en) * | 2008-05-14 | 2008-06-18 | Glaxo Wellcome Mfg Pte Ltd | Novel compounds |
US8426450B1 (en) | 2011-11-29 | 2013-04-23 | Helsinn Healthcare Sa | Substituted 4-phenyl pyridines having anti-emetic effect |
CN105745198B (zh) | 2013-11-08 | 2018-09-21 | 橘生药品工业株式会社 | 羧甲基哌啶衍生物 |
TWI649307B (zh) | 2014-05-07 | 2019-02-01 | 日商橘生藥品工業股份有限公司 | Cyclohexylpyridine derivative |
US10538491B2 (en) | 2015-03-16 | 2020-01-21 | Vanderbilt University | 4,5-substituted picolinamide and picolinonitrile metabotropic glutamate receptor 2 negative allosteric modulators |
CA3009325A1 (en) | 2015-12-22 | 2017-06-29 | Takeda Pharmaceutical Company Limited | Tripartite modulators of endosomal g protein-coupled receptors |
RU2020131446A (ru) | 2018-02-26 | 2022-03-28 | Оспедале Сан Раффаэле С.Р.Л. | Антагонисты nk-1 для применения в лечении глазной боли |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL111960A (en) | 1993-12-17 | 1999-12-22 | Merck & Co Inc | Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them |
SG52217A1 (en) | 1993-12-29 | 1998-09-28 | Merck Sharp & Dohme | Substituted morpholine derivatives and their use as therapeutic agents |
IL112778A0 (en) | 1994-03-04 | 1995-05-26 | Merck & Co Inc | Substituted heterocycles, their preparation and pharmaceutical compositions containing them |
US5972938A (en) | 1997-12-01 | 1999-10-26 | Merck & Co., Inc. | Method for treating or preventing psychoimmunological disorders |
EP1184036A2 (de) | 1998-03-19 | 2002-03-06 | Takeda Chemical Industries, Ltd. | Heterozyklische Verbindungen, ihre Herstellung und ihre Verwendung als Tachykininrezeptorantagonisten |
JPH11322748A (ja) * | 1998-03-19 | 1999-11-24 | Takeda Chem Ind Ltd | 複素環化合物、その製造法および用途 |
RU2238264C2 (ru) * | 1999-02-24 | 2004-10-20 | Ф.Хоффманн-Ля Рош Аг | Производные бензола или пиридина и фармацевтическая композиция на их основе |
RU2236402C2 (ru) * | 1999-02-24 | 2004-09-20 | Ф.Хоффманн-Ля Рош Аг | Производные 3-фенилпиридина и фармацевтическая композиция на их основе |
PT1394150E (pt) * | 1999-02-24 | 2011-02-17 | Hoffmann La Roche | Derivados de 4-fenilpiridina e a sua utilização como antagonistas dos receptores de nc-1 |
US6291465B1 (en) * | 1999-03-09 | 2001-09-18 | Hoffmann-La Roche Inc. | Biphenyl derivatives |
EP1103545B1 (de) * | 1999-11-29 | 2003-11-05 | F. Hoffmann-La Roche Ag | 2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramid |
US6303790B1 (en) * | 1999-11-29 | 2001-10-16 | Hoffman-La Roche Inc. | Process for the preparation of pyridine derivatives |
SI1303490T1 (sl) * | 2000-07-14 | 2008-10-31 | Hoffmann La Roche | N-oksidi kot predzdravila NK 1 receptorskega antagonista 4-fenil-piridin derivatov |
-
2001
- 2001-07-06 TW TW090116615A patent/TWI287003B/zh not_active IP Right Cessation
- 2001-07-09 US US09/901,311 patent/US6576762B2/en not_active Expired - Lifetime
- 2001-07-17 JO JO2001117A patent/JO2321B1/en active
- 2001-07-18 PE PE2001000730A patent/PE20020258A1/es not_active Application Discontinuation
- 2001-07-19 PA PA20018522801A patent/PA8522801A1/es unknown
- 2001-07-20 CZ CZ2003528A patent/CZ2003528A3/cs unknown
- 2001-07-20 AU AU8200501A patent/AU8200501A/xx active Pending
- 2001-07-20 IL IL15383701A patent/IL153837A0/xx active IP Right Grant
- 2001-07-20 MY MYPI20013445A patent/MY129224A/en unknown
- 2001-07-20 ES ES01960529T patent/ES2260265T3/es not_active Expired - Lifetime
- 2001-07-20 YU YU2803A patent/YU2803A/sh unknown
- 2001-07-20 HU HU0301272A patent/HU229231B1/hu unknown
- 2001-07-20 CN CNB018132863A patent/CN1192032C/zh not_active Expired - Lifetime
- 2001-07-20 MX MXPA03000367A patent/MXPA03000367A/es active IP Right Grant
- 2001-07-20 RU RU2003104794/04A patent/RU2276139C2/ru not_active IP Right Cessation
- 2001-07-20 SI SI200130532T patent/SI1305319T1/sl unknown
- 2001-07-20 KR KR10-2003-7001022A patent/KR100527214B1/ko active IP Right Grant
- 2001-07-20 JP JP2002514138A patent/JP4118673B2/ja not_active Expired - Lifetime
- 2001-07-20 NZ NZ523452A patent/NZ523452A/en unknown
- 2001-07-20 PT PT01960529T patent/PT1305319E/pt unknown
- 2001-07-20 EP EP01960529A patent/EP1305319B1/de not_active Expired - Lifetime
- 2001-07-20 DK DK01960529T patent/DK1305319T3/da active
- 2001-07-20 WO PCT/EP2001/008432 patent/WO2002008232A1/en active IP Right Grant
- 2001-07-20 AU AU2001282005A patent/AU2001282005B2/en not_active Expired
- 2001-07-20 DE DE60118569T patent/DE60118569T2/de not_active Expired - Lifetime
- 2001-07-20 PL PL01366173A patent/PL366173A1/xx not_active Application Discontinuation
- 2001-07-20 BR BR0112695-4A patent/BR0112695A/pt not_active IP Right Cessation
- 2001-07-20 CA CA2416874A patent/CA2416874C/en not_active Expired - Lifetime
- 2001-07-20 AT AT01960529T patent/ATE322496T1/de active
- 2001-07-23 UY UY26851A patent/UY26851A1/es not_active Application Discontinuation
- 2001-07-23 AR ARP010103499A patent/AR029875A1/es not_active Application Discontinuation
- 2001-07-23 GT GT200100148A patent/GT200100148A/es unknown
-
2002
- 2002-10-29 US US10/282,357 patent/US6624176B2/en not_active Expired - Lifetime
-
2003
- 2003-01-07 IL IL153837A patent/IL153837A/en unknown
- 2003-01-08 ZA ZA200300219A patent/ZA200300219B/en unknown
- 2003-01-17 HR HR20030031A patent/HRP20030031A2/xx not_active Application Discontinuation
- 2003-01-22 MA MA27006A patent/MA26933A1/fr unknown
- 2003-01-23 EC EC2003004446A patent/ECSP034446A/es unknown
- 2003-01-23 NO NO20030353A patent/NO20030353L/no not_active Application Discontinuation
-
2004
- 2004-02-16 HK HK04101077A patent/HK1058360A1/xx not_active IP Right Cessation
-
2006
- 2006-07-04 CY CY20061100918T patent/CY1106113T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE328871T1 (de) | 4-phenyl-pyridin-derivate verwendbar als neurokinin-1 rezeptor antagonisten | |
ATE322496T1 (de) | 4-phenylpyridin-derivate als neurokinin-1- rezeptor-antagonisten | |
ATE368659T1 (de) | Thrombinrezeptorantagonisten | |
ATE381565T1 (de) | 1,3,8-triaza-spiro 4,5 decan-4-onderivative als neurokininrezeptorantagonisten | |
ATE288898T1 (de) | Phenylethenyl- oder phenylethinylderivate als glutamatrezeptorantagonisten | |
ATE400558T1 (de) | Metabotropische glutamatrezeptor-antagonisten | |
DE60318697D1 (de) | Triazolderivate als tachykininrezeptor-antagonisten | |
DE60112051D1 (de) | Il-8 rezeptor antagonisten | |
DE60017110D1 (de) | Biphenylderivate als neurokinin-1 antagonisten | |
DE60126480D1 (de) | Il-8 rezeptor-antagonisten | |
DE50100358D1 (de) | Neue N-Triazolylmethyl-Piperazinderivate als Neurokininrezeptor-Antagonisten | |
NO20024554D0 (no) | IL-8 reseptorantagonister | |
NO20024367D0 (no) | IL-8 reseptorantagonister | |
NO20024366D0 (no) | IL-8 reseptorantagonister | |
SE0003996D0 (sv) | Receptorantagonister |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1305319 Country of ref document: EP |